Synonyms: Cytosar® | DepoCyte® | U-19920
cytarabine is an approved drug (FDA (1969), EMA (2001))
Compound class:
Synthetic organic
Comment: Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA.
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
No information available. |
Summary of Clinical Use |
Cytarabine is used to treat some types of leukemia including leukemia associated with meningitis. In August 2017 the US FDA approved a fixed-dose combination of cytarabine and daunorubicin (Vyxeos®) for the treatment of adults with two types of acute myeloid leukemia (AML): newly diagnosed therapy-related AML (t-AML) or AML with myelodysplasia-related changes (AML-MRC). |
External links |
For extended ADME data see the following: Electronic Medicines Compendium (eMC) Drugs.com European Medicines Agency (EMA) |